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Abstract: Neuroendocrine tumors (NETs) consist of a diverse family of tumors which are derived from the neuroendocrine system. 
Most NETs are well or moderately differentiated tumors with a relatively indolent growth pattern. However, these tumors can cause 
significant clinical disease due to release of functional products that mediate the carcinoid syndrome and other diverse sequela. They 
also can grow progressively and cause symptoms from local invasion or distant metastasis. NETs are optimally treated with surgery 
and somatosatin analogs (SSA’s) to control symptoms but are relatively insensitive to systemic chemotherapy. As a result, patients with 
advanced unresectable NETs have a poor prognosis. In 2011, two targeted therapies, sunitinib and everolimus were approved in the 
subset of progressive pancreatic NETs (pNETs). Everolimus is an oral inhibitor of the growth stimulatory mTOR pathway.
In Phase 2 trials in NETs and pNETs, everolimus was well tolerated and associated with some response and widespread disease sta-
bilization. In follow-up, randomized Phase 3 trials, everolimus was compared to placebo. In the RADIANT-2 trial, everolimus and a 
somatostatin analog were used in patients with functional NETs and treatment was associated with an an improvement in progression-
free survival (PFS). In the RADIANT-3 trial, patients with pNET were randomized to receive everolimus or placebo along with best 
supportive care. Everolimus was again associated with improvement in PFS compared to placebo and it has been approved by the FDA 
for patients with progressive pNET. Everolimus is associated with frequent low grade toxicity but is also notable for increased rates of 
infection as well as non-infectious pneumonitis. mTOR inhibition with everolimus represents a significant advance in the treatment of 
advanced neuroendocrine tumors.
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Background
Neuroendocrine tumors
Neuroendocrine tumors (NETs) consist of a diverse 
family of tumors which are derived from the neuroen-
docrine  system.  This  heterogeneous  population  of 
tumors frequently arise from embryonal neural crest 
cells, which are abundant in the epithelium of the 
gastrointestinal tract and bronchopulmonary   system.1 
However NETs can arise in other sites throughout 
the body. NETs have a wide range of   morphologic, 
functional  and  behavioral    characteristics.2  In  gen-
eral NETs are more indolent than epithelial tumors, 
though small cell and large cell morphology are asso-
ciated with aggressive proliferation.
The majority of NETs are low to   intermediate grade 
and  are  often  termed  carcinoid  tumors.    Carcinoid 
tumors represent a heterogeneous group of lesions but 
their incidence has markedly increased in the last 30 
years. An analysis of SEER data from a 25 year period3 
revealed that the incidence of carcinoid tumors had 
risen from 8.5 to 38.4 per million persons between 
1973 and 1997. The reason for this increase is not 
clear but may be related to greater standardization 
of the pathologic diagnosis and increased awareness 
of this disease. A subset of NETs are of pancreatic 
  origin4 and are termed islet cell carcinomas or pancre-
atic NETs (pNETs) and will be discussed separately 
in this review paper.
Within the GI tract, carcinoids are subclassified 
based on their tissue of origin and this relates to the 
associated  clinical  symptoms.  Foregut  carcinoids 
have low serotonin and rarely secrete active peptides 
but can metastasize, midgut tumors invariably secrete 
serotonin and cause the classic carcinoid syndrome,5 
hindgut tumors secrete a variety of gastrointestinal 
hormones.
“Functional”  NETs  may  synthesize  and  release 
a  variety  of  hormones  and  active  peptides  that  are 
associated with clinical symptoms. Most notably, this 
may lead to the carcinoid syndrome which consists 
of  flushing,  diarrhea,  and  other  symptoms  includ-
ing wheezing and cardiac symptoms.5,6 Somatostatin 
is an endogenous 14 amino acid peptide which binds 
to  somatostatin  receptors  and  has  a  predominately 
inhibitory  effect  on  the  release  of  many  gastroin-
testinal  hormones.7  The  clinical  utility  of  utilizing 
somatostatin is limited by the short half-life of this 
peptide in the circulation (less than three minutes). 
Octreotide is a synthetic peptide that mimics the effect 
of somatostatin but remains stable and active for a 
longer time in the circulation. Octreotide and other 
somatostatin analogs are useful in reducing symptoms 
in patients with carcinoid syndrome. One early study 
found rapid relief of symptoms in 22 of 25 patients 
with prolonged response in the majority of patients 
treated with octreotide.8 Long acting formulations are 
associated with prolonged relief in many patients9,10 
and are the standard of care for symptomatic tumors. 
The PROMID study,11 looked at the use of  long acting 
octreotide to control symptoms of functional NETs. 
Active treatment was effective in reducing symptoms 
compared  to  placebo  and  additionally  was  associ-
ated with delayed time to tumor progression (from 
6 months to 14.3 months, HR = 0.34, P  0.0001) 
even among patients without functional tumors.
Despite the ability to utilize symptomatic   treatment, 
the definitive therapy for functional or non-functional 
NETs is surgical resection. Once tumors are locally 
advanced  or  metastatic  their  management  becomes 
increasingly  challenging.  Some  metastatic  lesions 
remain suitable for resection12 but in general patients 
with  advanced  NETs  require  definitive  medical 
  therapy. The more common, well to moderately dif-
ferentiated  tumors  have  a  lower  proliferation  rate 
but are often unresponsive to chemotherapy. This is 
in noted contrast to poorly differentiated NETs such 
as small cell and large cell tumors which are more 
responsive  to  cytotoxic  chemotherapy.13,14 Cytotoxic 
therapy has been studied for the treatment of advanced 
well-differentiated NETs but has generally been disap-
pointing.15 High dose paclitaxel was given in a Phase 2 
trial16 which included 24 patients, 14 with carcinoid 
and 9 with pNET, there was response in only 2 patients 
(8%) with substantial   toxicity. A phase 2/3 trial looked 
at the combination of 5-FU with either doxorubicin or 
streptozocin for patients with advanced, unresectable 
NETs.17 Both regimens were associated with similar 
but  modest  response  rates  (15.9  and  16%  respec-
tively) and progression free survival intervals; with 
an improvement in overall survival in the 5-FU/strep-
tozocin arm (24.3 months vs. 15.7 months with 5-FU/
doxorubicin, P = 0.0267). This benefit was countered 
by an increase in renal toxicity in addition to baseline 
hematologic toxicity; given the modest response rates, 
  chemotherapy has traditionally been infrequently used 
in the treatment of metastatic carcinoid lesions.Everolimus in advanced neuroendocrine tumors
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Pancreatic NET
In the pancreas, NET’s arise from the islets and are 
often referred to as islet cell carcinoma but now more 
commonly known as pNET (pancreatic neuroendo-
crine carcinoma). Pancreatic neuroendocrine tumors 
(pNET) represent a small percentage of all pancre-
atic tumors:4 1.3% (with a 9.9% prevalence); but their 
incidence  is  rising.  Between  1977–1981  to  2002–
2005, the incidence rate of endocrine cancer of the 
pancreas rose more than 100% and advanced stage 
disease increased by 137%.18 This increase in pNET 
parallels the increasing frequency in NETs in general 
and likely relates to increased pathologic awareness 
and standardization of diagnosis. As with NETs in 
general, the definitive treatment of pNETs is surgical. 
When pNETs cause carcinoid symptoms, these can be 
controlled with somatostatin analogs.10 The majority 
of patients are unresectable as pNETs are frequently 
diagnosed at an advanced stage, with approximately 
65% of patients presenting with unresectable or meta-
static disease.19
Prior  to  2011  the  only  chemotheraputic  agent 
approved for use in pNETs was Streptozocin which is 
an alkylating agent isolated from streptomyces acro-
mogenes in the 1950s. The first study of its activity 
in pNET was reported in 1973 when Broder et al20 
reported a response rate of 50% in a single arm study 
with  52  patients,  which  represented  a  significant 
advance given the absence of effective therapy prior to 
this time. Streptozocin was approved by the FDA for 
this indication in 1976. Subsequent studies reported 
less robust response rates in pNET with streptozocin 
both when used alone21 and in combination with doxo-
rubicin.22 Some of the disparity in reported response 
is likely due to non-uniform response criteria utilized 
in some studies. Using radiographic response criteria 
McCollum et al,23 reported a response rate of only 6% 
among a series of 16 patients with advanced pNET   
(1 of 16 patients). In contrast a retrospective review of 
a three drug regimen, doxorubicin, 5-FU, streptozocin, 
was associated with a 39% response rate.24
Although there may be benefit with streptozocin 
combination regimens, the lack of prospective data 
has made it difficult to determine the most benefi-
cial therapy in this disease. Prior to 2011, no therapy 
had been approved by the FDA since the approval of 
Streptozocin in 1976. As a result patients with unre-
sectable pNETs have a poor prognosis. The median 
survival  time  for  patients  with  distant  metastatic 
disease is 24 months;19 the 5-year survival rate of 
patients with metastatic disease is 30% to 40%25 and 
has not changed for 20 years.26 This previously poor 
landscape has been significantly altered in 2011. We 
will report here on everolimus, an oral mTOR inhibi-
tor  which  has  now  been  approved  for  progressive 
pNET.   Additionally, in 2011 another targeted agent, 
the multitarget tyrosine kinase inhibitor, sunitinib, was 
approved for progressive pNET.27
NETs in hereditary syndromes point  
to mTOR as a therapeutic target
The search for novel active agents that would have 
potential use in NETs was enhanced by the association 
of NETs with several hereditary cancer syndromes.28 
NETs and especially pNETs are classically found in 
at least 4 hereditary cancer syndromes; multiple endo-
crine neoplasia type 1 (MEN1),29,30 tuberous sclerosis 
(TS),31  neurofibromatosis  type  1  (NF1),32  and  von 
Hippel-Lindau syndrome (vHL).33 In general, there 
is a specific increase in pNETs in these syndromes, 
though some are also associated with carcinoid from 
other sites.34 Interestingly the putative genes involved 
in  these  disorders  are  associated  with  constitutive 
activation of the mTOR pathway. Mammalian target 
of rapamycin, or mTOR, is a serine threonine tyrosine 
kinase that plays a critical role in cellular growth, pro-
liferation, and apoptosis.35,36 mTOR is part of the PI3K/
AKT pathway in which active signaling results in an 
increase in translation of proteins that are important in 
regulating cell cycle progression and maintaining pro-
liferation. In the setting of reduced nutrients or other 
cellular signals to limit growth, mTOR is inhibited and 
this leads to increased levels of CDK2 and cell cycle 
inhibition.37 In many human cancers mTOR signaling 
is dysregulated through several mechanisms including 
mutations in the pathway kinases,38 loss of inhibitory 
proteins (such as PTEN),39 or activating mutations in 
the signaling pathway.40 Besides mutations in the spe-
cific genes associated with the above mentioned cancer 
syndromes,41,42 upstream components of this signal-
ing pathway such as insulin like growth factor-143 
(IGF-1) and the IGF receptor,44 as well as vascular 
endothelial growth factor (VEGF) are overexpressed 
in NETs.45,46 Finally in support of the role of mTOR 
pathway in NETs, a global gene expression analysis 
of pNETs47 revealed that two important genes in the Oberstein and Saif
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mTOR pathway (tuberous sclerosis 2 and PTEN) were 
downregulated in most of the primary tumors. Altered 
levels of one or both of these proteins were identified 
in 85% of pNETs in this survey, strongly supporting 
the  role  of  the  mTOR  pathway  in    tumorogenesis. 
Thus targeting the mTOR complex downstream of 
these growth factors (IGF-1, IGFR and VEGF) may 
result in clinical benefit.
Inhibition of mTOR with everolimus
Early efforts to modulate aberrant mTOR   activity in 
malignancy utilized rapamycin (sirolimus).   Rapamycin 
is a macrolide antibiotic which binds to the cytoso-
lic protein, FK binding protein 12 (FKBP-12), which 
interacts with the mTOR complex and prevents down-
stream signaling.48 Mice that are deficient in PTEN (a 
tumor suppressor gene which is a negative regulator 
of the mTOR signaling pathway) are susceptible to 
developing a variety of malignancies.50 In this model, 
treatment with rapamycin was successful in normal-
izing protein function and reducing the rates of tumor 
development. Inhibitors of the mTOR pathway have 
been tested in a number of malignancies that are asso-
ciated with aberrant activation of the mTOR signal-
ing pathway,35 including breast cancer, head and neck 
malignancies, and lymphoma. Moreno and colleagues 
utilized this clinical rationale and demonstrated the 
clinical potential of blocking the mTOR pathway in 
NET.51 Rapamycin significantly inhibited cell prolif-
eration in carcinoid cell lines and was associated with 
significant tumor suppression in vivo.
Based on the above data, early clinical trials looked 
at the role of mTOR inhibition in NETs. The first 
rapamycin analog to be reported in this disease was 
temsirolimus. This drug was evaluated in 36 patients 
with progressive, unresectable NETs, 21 with carcinoid 
and 15 with pNET,52 but only 2 patients (5.6%) expe-
rienced an objective response to   therapy.   Everolimus, 
(originally  known  as  RAD001)  is  an  orally  active 
mTOR inhibitor that blocks the mTOR pathway by 
binding with high affinity to its intracellular recep-
tor  FKBP-12  in  a  fashion  similar  to    rapamycin.49 
Preclinical studies show that everolimus inhibits pro-
liferation of a variety of human solid tumors in vitro 
and in vivo.36 Everolimus has demonstrated efficacy 
in  renal  cell  carcinoma53  and  is  approved  for  this 
  indication.  The  initial  phase  I  trial  of  everolimus 
involved 92 patients with solid tumors54 (there was 
no report of patients with NETs on this trial). A MTD 
was not achieved but doses up to 10 mg/day were tol-
erated and the recommendation was to begin trials at 
doses of at least 5 mg/day.
In addition to everolimus, which is the focus of 
this review, there is ongoing interest in novel agents 
that target diverse components of the mTOR signaling 
pathway. These include GDC-0980,55 a class I PI3K 
and mTOR inhibitor, as well as pp242,56 an inhibitor 
of the active site of the mTOR complex.
Efficacy of Everolimus in NET
On the basis of the above preclinical data, Yao et al57 
conducted a single institution, Phase II trial of everoli-
mus in patients with advanced NETs. They treated each 
patient with a combination of everolimus at either 5 or 
10 mg/day and long acting octreotide (Sandostatin 
LAR 30 mg every 28 days). Prior treatment was per-
mitted; patients were required to have adequate bone 
marrow, renal, and hepatic function as well as ECOG 
performance status of 2 or less (ie, active for .50% 
of the day and capable of self-care). 60 patients were 
treated on this protocol, 30 with carcinoids and 30 
with pNET. There were 13 partial responses (22%) 
and 42 patients with stable disease (70%), there were 
no complete responses. The median progression free 
survival of patients was 60 weeks (95% CI, 54 to 66 
weeks). The encouraging results in this single institu-
tion, Phase II trial, led to additional trials in advanced 
functional NETs, in which everolimus was combined 
with octreotide; and in pNET, where everolimus was 
used alone or in combination with octreotide depend-
ing on patient symptoms. These trials are summarized 
below and in Table 1.
RADIANT-1
An  open  label  Phase  II  trial  was  initiated  to  look 
at  everolimus  in  patients  with  pNET.  This  trial, 
RAD001 in advanced neuroendocrine tumors-1 (or 
RADIANT-1), was a multinational, single-arm, Phase II 
trial.58 All patients had advanced pancreatic NETs who 
had progression despite prior use of cytotoxic che-
motherapy. All patients were treated with everolimus 
10 mg/day; in addition patients who had previously 
been receiving a somatostatin analog were continued 
on these agents. The study enrolled 160 patients, and 
demonstrated a response rate of 8.7% (PR), 84.7% of 
patients achieved at least stable disease. Median PFS Everolimus in advanced neuroendocrine tumors
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was 9.7 months in patients who received everolimus 
alone  (n  =  115)  and  16.7  months  in  patients  who 
received everolimus and octreotide. Median overall 
survival was 24.9 months in the first group and had 
not been reached in the second group. The differences 
between the 2 groups were not statistically significant. 
These results confirmed the robust rates of stable dis-
ease and a small percentage of objective responses 
seen in the earlier study and led to the initiation of 
2 large randomized, multi-center Phase III trials.
RADIANT-2
The RADIANT-2 trial looked at the role of adding 
everolimus or placebo to treatment with long-acting 
release (LAR) octreotide in patients with advanced 
NETs with carcinoid syndromes. This was a large, 
multi-national, randomized, placebo-controlled, Phase 
III trial. This study included 429 patients, all patients 
received octreotide LAR 30 mg IM every 28 days 
and were randomized to receive everolimus 10 mg/
day or placebo. The most frequent primary site of dis-
ease was the small intestine (52%), followed by the 
lung (10%), 6% of patients had a pancreatic primary 
site. All patients had well to moderately differenti-
ated  progressive  NETs  with  secretory  symptoms. 
Among  the  429  patients,  mPFS  was  16.4  months 
in the everolimus group compared to 11.3 months in 
the placebo group.60,61 Though the trial demonstrated 
that  everolimus  is  associated  with  a  reduced  risk 
of progression of 23%, the hazard ratio (HR: 0.77; 
P = 0.026) fell just short of the prespecified boundary 
of statistical significance (0.0246). Subset analysis by 
Anthony et al62 revealed that there was an improve-
ment  in  mPFS  among  patients  who  had  received 
somatostatin  analogs  prior  to  enrollment  (79%  of 
patients, mPFS was 14.3 vs. 11.1 months) and among 
those who had not received prior therapy with soma-
tosatin analogs (21% of patients, mPFS was 25.2 vs. 
13.6  months).  However  neither  subgroup  reached 
statistical significance.
RADIANT-3
The most robust data for everolimus was obtained in 
a randomized phase III study in 410 patients with pro-
gressive  advanced  pancreatic  NETs  (RADIANT-3). 
This  study  demonstrated  significant  improvements 
in PFS associated with everolimus as compared to 
placebo63 (11 months versus 4.6 months). Patients were 
included if they had low or intermediate grade NET 
defined as “advanced” (unresectable or metastatic), 
ECOG performance status of 2 or less (meaning they 
were  ambulatory,  able  to  care  for  themselves  and 
active for more than 50% of the day); they could have 
received prior chemotherapy or other treatment but not 
previous treatment with an mTOR inhibitor. The trial 
was double-blinded, patients received either 10 mg oral 
everolimus daily or placebo. In addition to study drug, 
patients received best supportive care which included 
somatostatin analogs in 40% of patients. The patient’s 
treatment was concealed until progression at which 
time they could cross-over to everolimus if they were 
previously receiving placebo. 410 patients were ran-
domized; most had well differentiated disease (80%), 
90% had evidence of liver metastasis. Patients were 
continued on treatment until they had progression of 
disease or unacceptable toxicity. The median duration 
of treatment in the everolimus group was 8.79 months, 
compared to 3.74 months in the placebo group.
PFS as determined by the local investigators was 
11.0 months vs. 4.6 months (hazard ratio for disease 
progression or death with everolimus, 0.35; P , 0.001). 
Response  rates  (using  standardized  radiographic 
criteria- Response Evaluation Criteria in Solid Tumors- 
RECIST)64 were low, 10 patients on the everolimus 
arm (5%) compared to 4 patients (2%) in the placebo 
arm. Most patients experienced stable disease as their 
best response (73 vs. 51%), and progressive disease 
as  best  response  was  seen  in  14%  of  patients  on 
everolimus compared to 42% of patients on placebo. 
Ultimately there was significant crossover with 73% 
(148 of 203) of the placebo arm patients receiving 
everolimus on progression. At the time of report, no 
difference was seen in median OS between the two 
groups.  Subset  analysis  of  the  RADIANT-3  trial 
was reported in abstract form. Shah et al,65 reported 
that  equal  patients  received  somatostatin  analogs 
(SSAs) on each arm (39 vs. 40%) and that there was a 
significant improvement in PFS regardless of the use 
of SSAs. Pommier and colleagues66 found that PFS 
was improved in patients regardless of  whether they 
received prior chemo (50%) or had no prior chemo-
therapy. In multivariate analysis (reported along with 
ASCO  2011-  J  Clin  Oncol  29:  2011  (suppl;  abstr 
e21091) performance status of 0, non-elevated base-
line neuron specific enolase (NSE) and absence of  liver 
involvement were associated with improved PFS.Everolimus in advanced neuroendocrine tumors
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These  results  in  RADIANT-3  compare  to  the 
results achieved with use of sunitinib in advanced 
pNET. In a randomized Phase III trial,27 sunitinib dem-
onstrated improvement in progression free   survival 
of 11.4 months compared to 5.5 months for placebo 
(P , 0.001).
Toxicity of Everolimus  
Therapy in NETs
As with any new drug it is important to evaluate the 
expected toxicity profile of this agent and to main-
tain awareness that long term data is lacking and 
vigilance is needed to identify emerging toxicities. 
In general studies in available mTOR inhibitors have 
shown similar dose limiting toxicities which are pri-
mary related to GI disturbance (including stomatitis), 
weakness,  fatigue,  and  thrombocytopenia  at  high 
doses.67  The  first  widely  studied  use  of  everoli-
mus and mTOR inhibitors in general is in attenuat-
ing rejection in the solid organ transplant setting. 
In  phase  I  studies,  the  most  commonly  reported 
toxicities  included  hypercholesterolemia,  hyper-
triglyceridemia, and mild hematologic toxicity with 
leukopenia  and  thrombocytopenia.68  In  both  the 
cardiac69 and renal transplant setting,70 everolimus 
has shown benefit and safety at daily doses of 1.5 
or 3 mg. In the initial Phase I trials of everolimus 
in solid tumors a higher daily dose was ultimately 
used.  The  most  commonly54  identified  toxicities 
were fatigue (34%), rash (48%), and GI toxicities 
(66%) which included stomatitis, nausea, vomiting, 
anorexia. Dose limiting toxicity was only seen in 
2 of 92 patients (2.1%), one with stomatitis, and one 
with hyperglycemia. A maximum tolerated dose was 
not established but the mean dose used for further 
trials has been 10 mg/day.
Prior to its approval for pNET, everolimus was 
approved for the treatment of renal cell carcinoma. 
In  this  indication  toxicity  was  comparable  to  that 
seen in solid organ transplant patients. For example, 
in the Phase III trial that demonstrated efficacy for 
everolimus,53,71 common toxicities which were more 
frequent in the everolimus arm compared to placebo, 
included fatigue (20%), stomatitis (40%), rash (25%), 
and hyperglycemia (50%). Additionally, pneumonitis 
has been reported with mTOR inhibitors and this was 
seen in 8% of patients, though all of the above side 
effects were rarely grade 3 or higher. Similar toxicity 
was  seen  with  temsirolimus,72  suggesting  that  this 
toxicity is a class effect of mTOR inhibitors.
Toxicity of mTOR inhibitors in NETs
In the previously described Phase II study of temsiroli-
mus,52 the most frequent adverse events were: fatigue 
(78% of patients), hyperglycemia (69% of patients), and 
rash/desquamation (64% of patients). Seven patients 
(of 37) developed pneumonitis considered as possibly 
related to temsirolimus, three of whom required drug 
discontinuation. Similar toxicities were seen in all tri-
als utilizing everolimus in NETs. In the single institu-
tion study57 by Yao et al, grade 1 or 2 toxicity was 
common but grade 3 toxicity was generally uncom-
mon; pneumonitis was seen in 9% of the patients on 
the 10 mg dose. In the phase 2, RADIANT-1 trial,58 
pneumonitis was seen in 8% of patients, all events were 
grade 1 or 2. In the phase 3, RADIANT-2 trial60 the 
most common side effects were similar and included 
frequent grade 1–2 toxicities including stomatitis (62 
vs. 14%), rash (37 vs. 12%), and fatigue (31 vs. 23%). 
The  most  frequent  drug-related  grade  3–4  adverse 
events  were  fatigue,  diarrhea,  and  hyperglycemia.   
Pulmonary events, including pneumonitis, were seen 
in 12% of patients on everolimus versus 0% of patients 
on the placebo arm.
Similar  toxicity  was  noted  in  the  phase  3,   
RADIANT-3 trial in which patients with pNET were 
randomized to everolimus at a dose of 10 mg/day 
or  placebo.  Adverse  effects  were  common  in  the 
everolimus  group  with  64%  of  patients  reporting 
stomatitis (vs. 17% in the placebo arm), 49% with 
rash (vs. 10%), 34% with diarrhea (vs. 10%) and 23% 
with infections (vs. 6%). Notably 12% of patients in 
the everolimus arm developed pneumonitis (vs. 0% 
in placebo). Atypical infections such as pulmonary 
tuberculosis,  bronchopulmonary  aspergillosis,  and 
reactivation of hepatitis B (each of which occurred 
in one patient) were also observed in association with 
everolimus therapy and 5 patients (2%) were felt to 
have grade 3–4 non-infectious pneumonitis or ILD.
Rare side effects
In  previous  experience  with  everolimus  and  other 
mTOR inhibitors, rare side effects have been observed 
and caution must be taken to be alert for these. Among 
the serious side effects reported are development of 
bronchiolitis obliterans with organizing pneumonia Oberstein and Saif
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(BOOP)  which  required  drug  discontinuation  and 
steroid therapy.54 In the transplant setting, everolimus 
has rarely been associated with severe pneumonitis,73 
diffuse alveolar hemorrhage,74 and other pulmonary 
complications.75 Pneumonitis has also been observed 
with  everolimus  therapy  for  renal  cell  carcinoma 
(14% of patients vs. 0% with placebo).76
Monitoring during therapy
Since some common side effects are metabolic, patients 
who begin therapy with everolimus should have cho-
lesterol, triglyceride, and glucose levels monitored at 
baseline and during therapy. In addition hematologic 
parameters  should  be  monitored    regularly.  There 
is an increased risk of infection, possibly owing to 
the  immunosuppressive  effect  of  everolimus  and 
patients should be monitored for signs of infection. 
In the event of infection, the product manufacturer 
recommends  discontinuation  of  the  drug.  There  is 
varying practice regarding checking hepatitis B and C 
prior to treatment depending on patient’s risk factors 
for  infection.  In  the  event  of  positivity,  anti-viral 
treatment should be administered with therapy or at 
least viral serologies should be monitored and treat-
ment adjusted accordingly. Respiratory toxicity can 
be substantial. Patients should be alerted to this pos-
sibility as the presentation of interstitial lung disease 
may be insidious. In some trials in renal cell cancer71 
(RECORD-1) patients were routinely screened with 
chest imaging but this was not done in the large trials 
in NETs. Patients should know to alert the physician 
with signs of worsening lung function such as cough, 
dyspnea with exertion, or fatigue and imaging should 
be pursued in these cases. Interstitial pneumonitis can 
often be reversed with prompt discontinuation of the 
drug and steroid treatment when necessary.
Conclusions
In  2  large  randomized  controlled  trials  in  NETs, 
everolimus has demonstrated benefit in patients with 
advanced,  unresectable  NETs.  To  date  the  benefit 
has been in increased time to progression, there are 
no reported trials (or abstracts) that suggest overall 
survival benefit. Although prolonged follow up from 
these large trials may be informative, it is possible 
that a survival benefit will not be achieved due to sub-
stantial cross-over at the time of progression (73% 
in RADIANT-3). It is also possible that the benefit 
of everolimus is not associated with survival benefit, 
only  prolonging  the  time  to  disease  progression. 
Objective response rates in the RADIANT-3 trial were 
low, suggesting that the primary benefit of everolimus 
is in stabilizing disease. In pancreatic NETs everoli-
mus was approved by the FDA for the treatment of 
progressive  pancreatic  neuroendocrine  tumors  that 
are  unresectable,  locally  advanced,  or  metastatic.   
We await further analysis of the RADIANT-2 trial to 
determine the role of this agent in other unresectable, 
advanced carcinoid tumors.
Everolimus is effective in patients who have previ-
ously received somatostatin therapy as well as patients 
who have received cytotoxic therapy.   Subset analysis 
suggests that patients with elevated levels of chro-
mogranin (CgA) and neuron-specific enolase (NSE) 
at baseline have improved outcomes, some tumor sub-
sets are also predictive of improved response though 
these subsets must be validated in dedicated studies.
Everolimus is generally well tolerated though grade 
1 or 2 toxicity is common and should be expected. The 
most common side effects are rash and stomatitis, met-
abolic abnormalities in glucose, phosphate, and lipid 
metabolism are also common and these parameters 
should be monitored regularly during therapy. Medi-
cal management is usually sufficient to handle these 
abnormalities and rarely requires discontinuation of 
therapy. Infection and non-infective pneumonitis are 
potentially more severe toxicities that may necessi-
tate discontinuation of everolimus. Signs of these tox-
icities should be monitored closely. In addition, long 
term follow up of everolimus in solid tumors is lack-
ing and clinicians should remain vigilant for unex-
pected toxicity.
The success of mTOR therapy in neuroendocrine 
tumors and the low rate of serious toxicity raise the 
possibility that everolimus may be suitable for com-
bination  therapy  with  cytotoxic  therapy  or  other 
inhibitors of the aberrant signaling cascade. Recent 
studies have been initiated to test the combination of 
everolimus with the VEGF inhibitor, bevacizumab. 
Additional trials are looking at the combination of 
everolimus  and  sorafenib,  a  multi-kinase  inhibi-
tor that also modulates downstream effectors in the 
mTOR pathway. There is also ongoing research in 
alternative somatostatin analogs (pasireotide) which 
may  have  greater  efficacy  than  currently  available 
somatostatin analogs.Everolimus in advanced neuroendocrine tumors
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In summary, the mTOR pathway appears to play 
an  important  role  in  neuroendocrine  tumors  which 
are identified in several hereditary syndromes that are 
associated with aberrant mTOR signaling. This has 
been validated specifically in the case of pancreatic 
NETs in which everolimus, an oral mTOR inhibitor, 
demonstrated  marked  improvements  in  progression 
free survival in patients who were heavily pre-treated 
and had progressive disease. Everolimus is the first new 
drug approved for this disease in more than 30 years 
and with the recently approved sunitinib,27 provides 
hope that this disease can be managed and prolonged 
periods of stable disease can be reliably achieved.
Clinical Highlights
•  Neuroendocrine  tumors  (NETs)  and  especially 
pancreatic NET (pNETs) are difficult to treat when 
they are advanced and unresectable.
•  Treatment of  advanced functional NETs with everoli-
mus plus octreotide demonstrated an improvement 
in PFS compared to palcebo (16/4 vs. 11.3 months, 
P = 0.026).
•  pNETs  generally  have  reduced  overall  survival 
compared to other NETs.
•  Although pNET only represents 1.3% of pancre-
atic tumors the incidence is rising.
•  65% of pNETs are advanced at diagnosis and the 
median overall survival for these patients is 24 
months with no improvement in the last 20 years.
•  Recently 2 agents were approved by the FDA for 
advanced pNET; everolimus and sunitinib.
•  Everolimus increased PFS in advanced pNET from 
4.6 to 11 months compared to placebo (P , 0.001).
•  Patients  tolerated  everolimus  with  concomitant 
somatostatin analog therapy.
•  Patients with PS-0 had the largest benefit in multi-
variate analysis.
•  Stomatitis,  rash,  and  diarrhea  are  common  but 
manageable  toxicities  of  everolimus  therapy. 
Patients should be monitored for hyperglycemia 
and hypertriglyceridemia.
•  Caution is required to monitor for infections (23% 
of  patients)  and  pneumonitis  (12%)  which  can 
become severe and limit therapy.
Abbreviations
SSA, somatostatin analogs; PFS, progression free sur-
vival; NET, neuroendocrine tumor; pNET, pancreatic 
neuroendocrine tumor; mTOR, mammalian target of 
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